A major metabolite of Δ1-tetrahydrocannabinol reduces its cataleptic effect in mice

Summary The results described here demonstrate that THC-induced catalepsy in mice can be substantially inhibited by the prior administration of ¹-THC-7-oic acid, the major metabolite of THC in most species including humans. This raises the possibility that the intensity and duration of action of THC may depend to a large degree on the levels of this metabolite at the sites of action.We thank the National Institute on Drug Abuse for supporting this project by grants DA-02043 and DA-02052 and for supplying all of the cannabinoids. One of us (S.B.) is also the recipient of a Research Scientist Award from NIDA. We are grateful to Kristen Carlson and Thomas Honeyman for helpful suggestions in preparing this report.     

Integrin antagonists

Integrins are a family of cell surface glycoproteins that mediate numerous cell-cell and cell-matrix interactions and are involved in biological processes such as tissue morphogenesis, leukocyte recirculation and migration, wound healing, blood clotting and immune response. Aberrant cell adhesion has been implicated in the pathogenesis of several diseases, including a number of inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and asthma, as well as cancer and coronary heart disease. As such integrins are seen as excellent targets for the development of therapeutic agents. This report begins with an examination of the structure of integrin molecules and their ligands and then goes on to review the current state of development of antiintegrin antagonists. Received 13 April 1999; received after revision 28 May 1999; accepted 28 May 1999     

H2 receptor antagonists and human granulopoiesis

Summary The effect of 2 H₂ receptor antagonists (ranitidine and cimetidine) on the in vitro growth of human granulomonopoietic precursors (CFU-GM) was studied. Ranitidine, although having an anti H₂ receptor activity much greater than that of cimetidine, displays the same toxicity for CFU-GM.Acknowledgments. This work was supported by CNR, Rome, PFCCN and AIRC, Milan.     

Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position

Summary Substitution of arginine for glutamine in the 4-position of a vasopressin V₁ antagonist has been reported to turn it into an agonist. We resynthesized this 4-arginine analog and synthesized additional cyclic and linear vasopressin antagonists containing a 4-arginine. The presence of a 4-arginine in the resynthesized and new analogs had relatively minor effects on their antivasopressin V₁ and V₂ antagonistic potencies.     

High potassium intake increases the plasma concentration and urinary excretion of vasopressin in the rat

Summary The effect of alterations of dietary potassium intake on the plasma concentration and the urinary excretion of vasopressin was studied in male rats. Ingestion of a high potassium diet resulted in increases in the plasma concentrations of potassium and vasopressin, systolic blood pressure, urine flow, and urinary vasopressin excretion. Ingestion of a low potassium diet had little effect on the plasma vasopressin concentration and systolic blood pressure but caused decreases in the plasma potassium concentration and urinary vasopressin excretion. The results indicate that physiological changes in the plasma potassium concentration or some other consequence of altered dietary potassium intake can affect vasopressin release and excretion.     

钙阻断剂与肿瘤治疗

抗药性是肿瘤化疗的最大障碍之一,具抗药性的肿瘤细胞药物外排功能很强,而钙阻断剂能抑制抗癌药物从抗药性肿癌细胞排出,导致细胞抗药性减弱,可用于肿囊化疗,有潜在的临床应用价值,但有副作用。故应寻求毒副作用小类似钙阻断剂的其他修饰物以促进肿癌化疗。     

Effects of blood sampling,anesthesia and surgery on plasma vasopressin concentration in rats

The influence of blood sampling, anesthesia and surgery on plasma vasopressin concentration was assessed in rats. Mean plasma concentration in conscious, chronically catheterized rats was 1.4±0.1 pg/ml (n=6). This value remained constant over repeated plasma samplings in the same animals. On the other hand, decapitation increased the plasma vasopressin concentration to 6.0±2.4 (in pg/ml) (n=6), inactin anesthesia to 2.9±0.6 (n=6), anesthesia and femoral cannulation to 13.3±5.8 (n=6) and surgery for renal micropuncture to 81.3±35.0 (n=6). It is concluded that the level of circulating plasma vasopressin is highly dependent on the sampling technique and is closely related to the extent of surgery.     

Tachykinins in regulation of gastric motility and secretion

The tachykinins constitute a family of neuropeptides with a common C-terminal amino acid sequence. The best known tachykinin is substance P. Tachykinins are found in the nerve plexuses and nerve fibers in the stomach of all species examined. The circular muscle layer is densely innervated, whereas the longitudinal layer and the mucosa are less intensively innervated. Tachykinins are also found in a significant number of afferent neurons with cell bodies in the dorsal root ganglia. Release of tachykinin can be demonstrated in response to both electrical stimulation of the vagus nerves and application of capsaicin. In the stomach all three known tachykinin receptors seem to be present. Although species variations exist, NK-2 receptors are generally present on the musculature, NK-1 receptors on both neurons and muscles, and NK-3 receptors on neurons only. Tachykinins stimulate motility in all parts of the stomach, but tachykinins also appear to inhibit motility in certain situations. Also, motility initiated centrally, mediated through the vagus nerves, is influenced by tachykinins. The precise role of tachykinin in the various motor programs in the stomach is not clear. Gastric acid secretion is influenced by tachykinins in several species. Tachykinins do not seem to act as neurotransmitters directly on parietal cells, but may have a modulatory function. The importance of tachykinins for the regulation of pepsinogen and hormone secretion from the stomach remains unclear. Received 24 August 1999; received after revision 1 December 1999; accepted 3 December 1999     

2005～2007年武汉亚洲心脏病医院钙拮抗剂应用分析

目的:分析武汉亚洲心脏病医院钙拮抗剂应用情况及发展趋势.方法:对该院2005年~2007年钙拮抗剂的用药金额、用药频度、消耗金额进行统计.结果:钙拮抗剂的消耗金额呈上升趋势,氨氯地平的消耗金额最高,左氨氯地平和硝苯地平控释片的用药频度占前两位.结论:长效二氢吡啶类钙拮抗剂具有广阔的市场前景.     

Vasopressin antagonists

Effects of vasopressin via V1a- and V2-receptors are closely implicated in a variety of water-retaining diseases and cardiovascular diseases, including heart failure, hyponatraemia, hypertension, renal diseases, syndrome of inappropriate antidiuretic hormone secretion, cirrhosis and ocular hypertension. As vasopressin receptors are found in many different tissues, vasopressin antagonists may benefit the treatment of disorders such as cerebral ischaemia and stroke, Raynaud’s disease, dysmenorrhoea and tocolytic treatment. V1b selective vasopressin antagonists are discussed in terms of their usefulness in the treatment of emotional and psychiatric disorders. The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders. The V1a/V2 non-selective vasopressin antagonist conivaptan is the first vaptan which is approved by the FDA for the treatment of euvolaemic hyponatraemia. Received 3 February 2006; received after revision 16 March 2006; accepted 26 April 2006